Search Results for "Crizotinib Src Kinase"

11:55 EDT 1st August 2014 | BioPortfolio

Matching Channels

Polo like kinase Plk 1

Polo-like kinase (Plk) is an important cell cycle regulatory kinase that has been implicated in a multitude of cell cycle events. Plks form a family of four different proteins that regulates many as...

MAP kinase kinase MEK Inhibitors

The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death.  The MAPK pathway has emerged as the crucial route between membrane-bound Ras...

Bcr Abl and Src Kinase Inhibitors

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t...

Checkpoint kinase 1 CHK 1

Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumo...

Kinases Raf Inhibitors

The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or...

Matching News

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

Genomic fusion testing for echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase genes plus targeted first-line crizotinib is not a cost effective treatment strategy for pati...

Novartis' Lead Ceritinib Could Capture Market Share From Pfizer

By Daniel Firl:A 21 Center Phase I Clinical Trial of Ceritinib (LDK378), Novartis A.G. (NVS), published its findings of patients with advanced non-small-cell lung cancer (NSCLC) in the New England Jou...

Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)–anaplastic lymphoma kinase (ALK) acute myeloid leukemia

Crizotinib Not Cost-Effective, Says Canadian Study

Costly targeted therapies like crizotinib are changing cancer care, but can patients and healthcare systems afford to pay for them? Medscape Medical News

ALK Inhibition With Crizotinib in Advanced NSCLC

Does NSCLC treatment with crizotinib yield clinical benefit -- for patients who are beyond progressive disease? Annals of Oncology

Phase 1 trial finds ceritinib suppresses growth of both crizotinib-resistant and crizotinib-sensitive lung tumors with manageable side effects

Although the targeted cancer treatment drug crizotinib is very effective in causing rapid regression of a particular form of lung cancer, patients' tumors inevitably become resistant to the drug. Now...

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Phase I study findings suggest the investigational drug ceritinib is effective in patients with advanced non-small-cell lung cancer with anaplastic lymphoma kinase gene rearrangement, even in those wh...

Pfizer's Xalkori rides on in first-line NSCLC

Pfizer is now poised to tout its anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) as a standard of care in both the first and second-line setting for patients with ALK-positive advanced...

Matching PubMed Articles

The design of potent and selective inhibitors to overcome clinical ALK mutations resistant to crizotinib.

Crizotinib (1), an ALK receptor tyrosine kinase inhibitor approved by the FDA in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in...

Crizotinib: A comprehensive review.

Anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers. ALK-positivity confers sensitivity to small-molecule ALK kinase inhibitors, such as c...

Successful Crizotinib Rechallenge After Crizotinib-induced Interstitial Lung Disease.

We report the case of a 70-year-old Japanese male diagnosed with advanced lung adenocarcinoma harboring the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene. As...

Managing treatment-related adverse events associated with Alk inhibitors.

Anaplastic lymphoma kinase (ALK) rearrangements have been identified as key oncogenic drivers in a small subset of non-small-cell lung cancers (nsclcs). Small-molecule Alk kinase inhibitors such as cr...

Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer.

To the Editor: Shaw and colleagues (March 27 issue)(1) report that ceritinib can overcome crizotinib resistance in patients with non-small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma ki...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement